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ABSTRACT  
Pre-eclampsia is a major cause of maternal and fetal mortality in pregnancy. The identification of genetic 
variants which predispose to pre-eclampsia demands large DNA collections from affected mothers and 
babies and controls, with reliable supporting phenotypic data. The InterPregGen study has assembled a 
consortium of researchers from Europe, Central Asia and South America with the aim of elucidating the 
genetic architecture of pre-eclampsia. The MoBa collection is playing a vital role in this collaborative 
venture, which has the potential to provide new insights into the causes of pre-eclampsia, and provide a 
rational basis for novel approaches to prevention and treatment. 
 
This is an open access article distributed under the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction 
in any medium, provided the original work is properly cited. 
 
 
INTRODUCTION 
 
The InterPregGen consortium, a multinational collabo-
ration between research groups from Europe, Central 
Asia and South America, is seeking to identify genetic 
factors which predispose to pre-eclampsia, a quest 
which has proved challenging to investigators from 
around the world for decades. Pre-eclampsia is the 
most serious of the hypertensive disorders of pregnan-
cy, with an incidence ranging from 2-5% of pregnan-
cies in Western Europe and North America to as high 
as 18% in parts of Africa [1,2]. Advances in maternity 
care have improved the outlook for pre-eclampsia, but 
it nevertheless remains a significant cause of maternal 
mortality even in countries with well-developed health 
care provision [3]. Exact figures are not available from 
many developing countries, but on a conservative esti-
mate the complications of pregnancy-related hyperten-
sion account annually for over 50,000 maternal deaths 
worldwide [4]. Pre-eclampsia also has grave effects on 
the developing child, resulting in fetal growth restric-
tion, stillbirth and sudden infant death. Expedited pre-
mature delivery contributes to perinatal morbidity, and 
pre-eclampsia is associated globally with an estimated 
900,000 perinatal deaths annually [4]. 
 The clinical features of pre-eclampsia are maternal 
hypertension and proteinuria developing after the 20th 
week of gestation; these are manifestations of wide-
spread vascular endothelial dysfunction. It is possible 
that this is a common end point to diverse pathogenetic 
mechanisms, but the two-stage theory is a useful 
model, supported by observational and experimental 
evidence [5]. In the first stage, inadequate invasion of 
maternal uterine tissues by fetal trophoblast cells results 
in poor vascular perfusion of the placenta. The second 
stage, maternal endothelial dysfunction, results from 
the release of damaging factors from the placenta into 
the maternal circulation. One such factor is sFlt-1, a 
soluble growth factor receptor which binds vascular 
endothelial growth factor (VEGF) and placental growth 
factor (PlGF), interfering with their function in main-
taining the integrity of maternal vascular endothelium 
[6]. For the geneticist, an important feature of this 
model is the involvement of two genomes – fetal and 
maternal – in the pathogenesis of the disorder. 
 
Evidence for genetic factors  
Epidemiological studies over the past five decades have 
provided robust and consistent support for the clinical 
observation that pre-eclampsia runs in families. First 
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degree relatives of affected women have a 2- to 3-fold 
increase in risk of pre-eclampsia [7-10]. Furthermore, 
a pregnancy fathered by a man who was himself born 
of a pre-eclamptic pregnancy is twice as likely to be 
affected by pre-eclampsia [11]. A study of parous 
monozygotic and dizygotic female twin pairs on the 
Swedish Twin Register estimated the heritability of 
pre-eclampsia as 54% [12]. Subsequent analysis of 
over 700,000 births on the Swedish Birth Registry esti-
mated pre-eclampsia heritability conferred by maternal 
genes as 35% (95% CI 33-36%) and that due to fetal 
genes as 20% (95% CI 11-24%), with similar contri-
butions from maternally and paternally inherited genes 
[13]. A complex model of inheritance is likely, invol-
ving multiple genes with modest individual effect sizes. 
 These observations justify the search for genetic 
variants in mothers and babies which confer sus-
ceptibility to pre-eclampsia. Genetic studies offer an 
important advantage in the identification of novel 
pathogenetic mechanisms in diseases of pregnancy, as 
they circumvent the practical and ethical challenges of 
obtaining suitable maternal and fetal tissue early in 
pregnancy, when trophoblastic invasion of maternal 
tissues occurs; investigation of genetic variation in 
mother and offspring can be conducted on DNA ob-
tained at any time. Furthermore, in a disorder such as 
pre-eclampsia with a rapidly progressive pathophysio-
logy it is often difficult to distinguish between causal 
factors and secondary phenomena resulting from 
disease processes. Genetic variation which proves to 
be associated with disease is guaranteed to predate the 
disease process. 
 
Genetic studies of pre-eclampsia  
Genome-wide linkage studies of pre-eclampsia, analy-
sing families with two or more affected women from 
Australasia, Iceland, Finland and Holland, have each 
identified loci which appear to show linkage with pre-
eclampsia in their populations, but these results have 
not been independently replicated [14-18]. Many can-
didate genes have been tested for association with pre-
eclampsia, but in common with the experience in other 
complex disorders, these have generated inconsistent 
results [19]. Meta-analysis of published candidate gene 
studies has provided some support for genetic associa-
tion with polymorphic loci in genes encoding coagula-
tion factors II and V, the renin-angiotensin system, and 
factors such as methylene tetrahydrofolate reductase 
(MTHFR) and endothelial nitric oxide synthase (eNOS 
or NOS3) which play a role in maintaining endothelial 
integrity [20-22]. It is nevertheless noteworthy that one 
published meta-analysis concluded that the quality of 
the evidence from primary genetic association studies 
is frequently compromised by such factors as small stu-
dy size, or inadequate genotyping quality control [20]. 
 A major cause of the lack of success in identifying 
susceptibility genes has been the limited statistical 
power of the majority of studies performed to date. It 
is now apparent that many common genetic variants 
which predispose to complex disorders have individu-
ally small effect sizes. These variants are therefore dif-
ficult to detect by linkage analysis but can be detected 
with much higher power using genetic association 
study designs [23]. Interest is also growing in the 
contribution made by rare variants with larger effect 
sizes than those of common alleles. In either of these 
scenarios, the chromosomal locations of disease-
predisposing variants can be detected by genetic 
association, but only with sufficiently large numbers of 
disease cases to confer adequate statistical power, and 
only by applying rigorously defined thresholds of 
statistical significance to constrain the rate of false po-
sitive results [23]. It is also of note that genetic studies 
in pre-eclampsia have focused on the maternal genome 
with relatively few studies considering the fetal 
genome, in spite of the epidemiological evidence for a 
fetal contribution to the heritability of the disorder.  
 The InterPregGen consortium was formed to address 
these deficiencies, aiming firstly to include a suffici-
ently large number of subjects with rigorously defined 
pre-eclampsia to provide adequate statistical power for 
association studies to detect genetic variants with small 
effect sizes; secondly, to use genome-wide association 
screening (GWAS) to scan both the maternal and fetal 
genomes for variants that predispose to pre-eclampsia. 
Also, the majority of larger published genetic studies 
in pre-eclampsia have been conducted in women of Eu-
ropean ancestry, where the incidence of pre-eclampsia 
is amongst the lowest in the world. Therefore a further 
objective of the InterPregGen study was the inclusion 
of populations from different ethnic backgrounds in 
Europe, Central Asia and South America. 
 
 
THE INTERPREGGEN STUDY DESIGN 
 
Subjects  
InterPregGen is making use of several large biobanked 
DNA collections for studies of pre-eclampsia in 
Western Europe. These include the Norwegian Mother 
and Child Cohort Study (MoBa) [24,25]; the Nord-
Trøndelag Health Study (HUNT) [26]; FINNPEC (The 
Finnish Genetics of Pre-eclampsia Consortium) [27]; 
GOPEC (UK Genetics of Pre-eclampsia study) [28] 
and deCODE Genetics’ Icelandic collection [29]. A 
further 4000 Central Asian mother-father-baby trios 
affected by pre-eclampsia are being recruited in 
Kazakhstan and Uzbekistan as part of the study. 
InterPregGen is also using genome-wide data on 2000 
pre-eclamptic women and 2000 controls from the 
GenPE study of pre-eclampsia in Colombia, South 
America [30] (Table 1). 
 The diagnosis of pre-eclampsia is based on an inter-
national definition, requiring new-onset hypertension 
(systolic blood pressure ≥ 140 mm Hg; diastolic blood 
pressure ≥ 90 mm Hg), associated with proteinuria     
(≥ 300 mg/L) after the 20th week of gestation [31]. 
Recruitment of UK, Central Asian and Colombian 
subjects was made at the time of diagnosis; Finnish 
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Table 1.  Sources and number of samples available for 
genotyping in the InterPregGen study. GWAS: genome-wide 
association screening. 
 
Biobank 
Country of 
origin 
Maternal 
PE cases 
Fetal 
PE Cases Controls 
 Samples for GWAS 
 GOPEC  UK 1800 1000   6000 
 deCODE Iceland 1800 1000 36000 
 Kazakhstan Kazakhstan 1000 1000   1000 
 Uzbekistan Uzbekistan 1000 1000   1000 
 GenPE Colombia 2000 –   2000 
 Total samples for GWAS 7600 4000 46000 
 Samples for follow-up genotyping 
 MoBa Norway 1200 1200   1200 
 HUNT Norway 1000 600   1000 
 FINNPEC Finland   600   600     600 
 Kazakhstan Kazakhstan 1000 1000   1000 
 Uzbekistan Uzbekistan 1000 1000   1000 
 Total samples for follow-up 4800 4400   4800 
 
 
 
subjects were recruited prospectively or retrospective-
ly; MoBa subjects are selected from a prospectively-
recruited pregnancy cohort; Icelandic and HUNT sub-
jects were ascertained by linkage to medical registries 
and scrutiny of obstetric records. 
 The majority of control subjects are women with no 
history of hypertension (blood pressure <140/90 mm 
Hg) recruited during pregnancy. For Icelandic and UK 
subjects control data is provided by extensive existing 
GWAS data from population cohorts of respectively 
36000 and 6000 individuals. Population control data 
have been used successfully for the identification of 
genetic associations with many complex disorders 
[32]; providing the condition under investigation has a 
low population frequency (<10%) the advantages of 
extensive control data more than compensate for the 
small reduction in statistical power resulting from 
misclassification of cases as controls. 
 All participants in the study have provided informed 
consent for the use of their samples, or those of their 
babies, in genetic studies. Approval for use of the 
samples and associated clinical data has been obtained 
from Research Ethics Committees in their country of 
origin, and over-arching approval for the InterPregGen 
study has been provided by the University of Notting-
ham Research Ethics Committee. 
 
Genome-wide association screening (GWAS)  
The study is using genome-wide association screening 
as the primary strategy for discovery of genetic 
variants which are associated with pre-eclampsia. The 
principles of GWAS have been well-described else-
where [33]: case and control subjects are genotyped at 
600,000 to 2.5 million single nucleotide polymorph-
isms (SNPs) selected to capture the majority of com-
mon genetic variation across the genome. In addition 
to directly genotyped SNPs, thousands of additional 
genotypes at ungenotyped polymorphisms can be 
inferred by “imputation” algorithms [34] that use 
correlation (linkage disequilibrium) between alleles at 
nearby SNPs. Imputation requires knowledge of the 
patterns of linkage disequilibrium and for many popu-
lations these patterns are readily available from public 
resources such as HapMap [35] and 1000 Genomes 
[36]. However genome-wide linkage disequilibrium 
patterns are unavailable for Central Asian populations 
as they are not represented in publicly available 
databases. To supply this lack of linkage disequilibri-
um data from Central Asian populations, InterPregGen 
is undertaking whole genome sequencing of 100 
Kazakh and 100 Uzbek subjects. 
 To maximise the statistical power of the study in a 
cost-effective way, InterPregGen is making use of 
GWAS data generated in the course of earlier studies 
in maternal and control samples from Iceland, the UK 
and Colombia. Additional GWAS is being undertaken 
using Illumina genome-wide arrays on offspring of 
pre-eclamptic pregnancies from Iceland and the UK, 
and also on newly collected maternal-fetal cases and 
controls from Central Asia. GWAS data is therefore 
available from a total of 7600 maternal cases and 4000 
fetal cases (Table 1). 
 
GWAS data analysis  
For each study population with GWAS genotypes, all 
directly genotyped and imputed SNPs are tested for 
disease association in pre-eclampsia mothers and 
babies by logistic regression assuming an additive 
genetic model (SNP genotypes coded 0, 1, or 2). For 
each study population with GWAS genotypes from 
pre-eclamptic mother-baby pairs, SNPs are also tested 
for evidence that maternal-fetal genotype interaction 
increases susceptibility to pre-eclampsia. Allelic odds 
ratios (OR) provided for each population by logistic 
regression analysis are combined in a meta-analysis to 
generate an overall OR for each SNP. The selection of 
SNPs for subsequent replication genotyping is based 
on the results of meta-analysis, with priority given to 
those with the lowest p-values. To adjust for the mul-
tiple statistical tests conducted in the course of GWAS, 
a meta-analytic p-value below 5x10–8 is applied for 
genome-wide significance (see [37] for an overview of 
GWAS meta-analysis methods). 
 
Rare variants  
While the success of recent GWAS studies is im-
pressive, a substantial part of the heritability remains 
unaccounted for and there are reasons to believe that 
variants with substantial or large effects remain un-
detected [38]. The selection of SNPs for commercial 
GWAS arrays has been largely designed to detect 
common allelic variants with a population frequency of 
>5%. There is growing interest in the contribution of 
rarer alleles to heritability of common disorders. 
InterPregGen is addressing this by taking advantage of 
the unique and extensive pedigree information and 
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whole-genome sequencing data available for the 
Icelandic population [39], which allows for reliable 
detection of variants with 0.1% frequency or higher. 
Significant associations of pre-eclampsia with rare 
alleles in the Icelandic population are then tested by 
genotyping in other collections. 
 
Follow-up genotyping  
A vital component of genetic studies based on 
genome-wide screening is replication genotyping in 
independent sample collections to confirm positive 
associations detected by genome-wide screening. The 
European cohorts, MoBa, HUNT and FINNPEC, are 
providing 2800 maternal cases, 2400 fetal cases, and 
2800 controls for replication studies. The Central Asian 
collections will provide a further 2000 affected mothers 
and babies and 2000 controls (Table 1). Importantly, in 
the cohorts used for GWAS and for replication 
genotyping affected mother-baby pairs can be linked 
for analysis of maternal-fetal gene interactions. 
 Two related strategies of follow-up genotyping in 
the replication sets are used. A small number of SNPs 
with the most significant p-values on analysis of 
GWAS data are earmarked for fast track replication 
genotyping using mass spectrometry or allele-specific 
hybridisation technology. A larger number of SNPs 
with more modest evidence for association with pre-
eclampsia will be evaluated by custom-designed geno-
typing array technology in the replication sets. 
 InterPregGen benefits from the availability of affec-
ted mother-father-baby trios in many of its cohorts. 
SNPs which are associated with pre-eclampsia suscep-
tibility in babies are also genotyped in all available 
fathers of pre-eclampsia babies to determine if the 
ratio of allelic transmissions to PE children is different 
for heterozygous fathers and mothers, to test for 
parent-of-origin (imprinting) effects. The approach for 
examining parent-of-origin effects in Icelandic data 
will differ, due to the richness of existing Icelandic 
whole-genome data, providing two independent app-
roaches to test for imprinting effects. Through whole-
genome sequencing of Icelandic individuals, long-range 
haplotype phasing and parental-origin determination the 
deCODE dataset provides complete information of the 
parental-origin of each allele, without additional geno-
typing of paternal samples. 
 
 
CLINICAL TRANSLATION 
 
We anticipate that the research effort will identify 
functional DNA variants, or their proxies, which pre-
dispose to pre-eclampsia and its complications, leading 
to enhanced understanding of the underlying disease 
process. InterPregGen will explore the potential for 
translating this information into clinical benefits 
through risk-profiling and the development of novel 
predictive markers. Currently the prediction of women 
at high risk of pre-eclampsia depends on clinical 
criteria, including the identification of risk factors at 
antenatal booking [40]. These include primiparity, 
multiple pregnancy, a previous history of pre-
eclampsia, obesity, and evidence of hypertension, 
diabetes or renal disease prior to pregnancy. Even 
amongst these high-risk women only a minority will 
develop pre-eclampsia (about 15%), and better predic-
tive models are required. The potential for genetic 
profiling in identifying individuals at risk of complex 
disorders has not yet been realised for the majority of 
diseases; this may reflect the incomplete catalogue of 
genes associated with these disorders. In the case of 
pre-eclampsia, it is possible that both maternal and 
paternal genotypes are of importance. InterPregGen 
will identify a panel of maternal and paternal geno-
types and examine their value as “stand-alone” risk 
markers, and in predictive profiles in combination with 
clinical risk factors. In this regard the availability of 
extensive and reliable clinical information collected 
during pregnancy will be of vital importance in the 
evaluation of predictive models. The identification of 
metabolic pathways implicated by susceptibility genes 
in the pathogenesis of pre-eclampsia will highlight 
metabolites which are likely targets for the develop-
ment of plasma or urinary biomarkers as cost-effective 
alternatives to genetic profiling. 
 
 
ROLE OF MOBA IN THE INTERPREGGEN STUDY 
 
MoBa is a unique collection of samples and data 
gathered prospectively at the time of pregnancy. For 
researchers into the genetics of complex disorders of 
pregnancy such as pre-eclampsia MoBa offers the 
advantages of a searchable database of reliable clinical 
information which can be used to identify cases and 
controls which fulfil the inclusion criteria of the study 
with a high degree of confidence. The well-managed 
biobanking facility ensures that DNA of dependable 
quality is available for genotyping studies from large 
numbers of cases and controls, a vital requirement for 
adequately powered genetic association studies. In con-
trast to many case-control collections, MoBa includes 
data and DNA samples from the partners and babies of 
pregnant women, which will enable InterPregGen to 
explore both maternal and fetal genomes, the inter-
actions between maternal and fetal gene variants, and 
the contribution of paternal genes to pre-eclampsia. 
The biobanking expertise of MoBa partners in the 
InterPregGen study is proving invaluable in the 
discussion of ethical policies, and in the development 
of procedures for the newly formed biobanks in 
Uzbekistan and Kazakhstan. 
 
 
CONCLUSION 
 
The identification of genetic factors which predispose 
to pre-eclampsia is a large undertaking, in which 
MoBa has a key role. InterPregGen is conducting the 
largest ever genome-wide association screen of 
maternal and fetal genes and their interactions in this 
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disorder, and is also the first with adequate power to 
investigate the role of genetic imprinting (parent-of-
origin effect). The ability to compare the genetic 
architecture of pre-eclampsia in subjects from three 
continents may give insights into the source of 
variation in the frequency of the condition across 
different ethnic groups. The prospects are good for 
novel findings which will ultimately translate into a 
better understanding and management of a condition 
which remains one of the major killers of pregnant 
women and their babies throughout the world. 
ACKNOWLEDGMENTS 
 
InterPregGen has received funding from the European Union 
Seventh Framework Programme ([FP7/2007-2013] 
[FP7/2007-2011]) under grant agreement no. 282540. 
 
LINKS 
www.interpreggen.org 
 
CONFLICT OF INTEREST  
The authors declare that they have no conflict of interest. 
 
 
REFERENCES 
 
1. Lie RT, Rasmussen S, Brunborg H, Gjessing HK, Lie-Nielsen E, Irgens LM. Fetal and maternal contributions 
to risk of pre-eclampsia: population based study. BMJ 1998; 316: 1343-7. 
2. Villar J, Say L, Gulmezoglu AM, Meraldi M, Lindheimer MD, Betran AP, Piaggio G. Eclampsia and pre-
eclampsia: a health problem for 2000 years. In: Critchly H, MacLean A, Poston L, Walker J, editors. Pre-
eclampsia. London: RCOG Press, 2003: 189-207. 
3. Cantwell R, Clutton-Brock T, Cooper G, Dawson A, Drife J, Garrod D, et al. Saving Mothers’ Lives: Review-
ing maternal deaths to make motherhood safer: 2006-2008. The Eighth Report of the Confidential Enquiries 
into Maternal Deaths in the United Kingdom. BJOG 2001; 118 (Suppl 1): 1-203. 
4. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009; 33: 130-7. 
5. Roberts JM, Hubel CA. The two stage model of preeclampsia: Variations on the theme. Placenta 2009; 30 
(Suppl A): S32-7. 
6. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine 
kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J 
Clin Invest 2003; 111: 649-58. 
7. Chesley LC, Annitto JE, Cosgrove RA. The familial factor in toxemia of pregnancy. Obstet Gynecol 1968; 
32: 303-11. 
8. Sutherland A, Cooper DW, Howie PW, Liston WA, MacGillivray I. The incidence of severe pre-eclampsia 
amongst mothers and mothers-in-law of pre-eclamptics and controls. Br J Obstet Gynaecol 1981; 88: 785-91. 
9. Arngrimsson R, Bjornsson S, Geirsson RT, Bjornsson H, Walker JJ, Snaedal G. Genetic and familial predis-
position to eclampsia and pre-eclampsia in a deﬁned population. Br J Obstet Gynaecol 1990; 97: 762-9. 
10. Cincotta RB, Brennecke SP. Family history of pre-eclampsia as a predictor for pre-eclampsia in primigravidas. 
Int J Gynaecol Obstet 1998; 60: 23-7. 
11. Esplin MS, Fausett MB, Fraser A, Kerber R, Mineau G, Carrillo J, Varner MW. Paternal and maternal 
components of the predisposition to preeclampsia. N Engl J Med 2001; 344: 867-72. 
12. Salonen Ros H, Lichtenstein P, Lipworth L, Cnattingius S. Genetic effects on the liability of developing pre-
eclampsia and gestational hypertension. Am J Med Genet 2000; 91: 256-60. 
13. Cnattingius S, Reilly M, Pawitan Y, Lichtenstein P. Maternal and fetal genetic factors account for most of 
familial aggregation of preeclampsia: a population-based Swedish cohort study. Am J Med Genet [A] 2004; 
130A: 365-71. 
14. Arngrímsson R, Sigurõardóttir S, Frigge ML, Bjarnadóttir RI, Jónsson T, Stefánsson H, et al. A genome-wide 
scan reveals a maternal susceptibility locus for pre-eclampsia on chromosome 2p13. Hum Mol Genet 1999; 8: 
1799-1805. 
15. Moses EK, Lade JA, Guo G, Wilton AN, Grehan M, Freed K, et al. A genome scan in families from Australia 
and New Zealand conﬁrms the presence of a maternal susceptibility locus for pre-eclampsia, on chromosome 
2. Am J Hum Genet 2000; 67: 1581-5. 
16. Laivuori H, Lahermo P, Ollikainen V, Widen E, Häivä-Mällinen L, Sundström H, et al. Susceptibility loci for 
preeclampsia on chromosomes 2p25 and 9p13 in Finnish families. Am J Hum Genet 2003; 72: 168-77. 
17. Harrison GA, Humphrey KE, Jones N, Badenhop R, Guo G, Elakis G, et al. A genomewide linkage study of 
preeclampsia/eclampsia reveals evidence for a candidate region on 4q. Am J Hum Genet 1997; 60: 1158-67. 
18. Lachmeijer AMA, Arngrimsson R, Bastiaans EJ, Frigge ML, Pals G, Sigurdardóttir S, et al. A genome-wide 
scan for preeclampsia in the Netherlands. Eur J Hum Genet 2001; 9: 758-64. 
19. Chappell S, Morgan L. Searching for genetic clues to the causes of pre-eclampsia. Clin Sci 2006; 110: 443-58.  
20. Staines-Urias E, Ioannidis JPA, Paez MC, Keating BJ, Doyle P, Dudbridge F, et al. Genetic association studies 
in pre-clampsia: systematic meta-analyses and field synopsis. Int J Epidemiol 2012; 41: 1764-75. 
146  L. MORGAN ET AL. 
 
21. Dai B, Liu T, Zhang B, Zhang X,Wang Z. The polymorphism for endothelial nitric oxide synthase gene, the 
level of nitric oxide and the risk for pre-eclampsia: A meta-analysis. Gene 2013; 519: 187-93. 
22. Buurma AJ, Turner RJ, Driessen JH, Mooyaart AL, Schoones JW, Bruijn JA, et al. Genetic variants in pre-
eclampsia: a meta-analysis. Hum Reprod Update 2013; 19: 289-303. 
23. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996; 273: 1516-7. 
24. Magnus P, Irgens LM, Haug K, Nystad W, Skjaerven R, Stoltenberg C and the MoBa Study Group. Cohort 
profile: The Norwegian Mother and Child Cohort Study (MoBa). Int J Epidemiol 2006; 35: 1146-50. 
25. Rønningen KS, Paltiel L, Meltzer HM, Nordhagen R, Lie KK, Hovengen R, et al. The biobank of the Norwe-
gian Mother and Child cohort study. Eur J Epidemiol 2006; 21: 619-25. 
26. Roten LT, Johnson MP, Forsmo S, Fitzpatrick E, Dyer TD, Brennecke SP, et al. Association between the 
candidate susceptibility gene ACVR2A on chromosome 2q22 and pre-eclampsia in a large Norwegian 
population-based study (the HUNT study). Eur J Hum Genet 2008; 17: 250-7. 
27. Kaartokallio T, Klemetti MM, Timonen A, Uotila J, Heinonen S, Kajantie E, et al. Microsatellite poly-
morphism in the heme oxygenase-1 promoter is associated with non-severe and late-onset preeclampsia. 
Hypertension 2014; 64: 172-7. 
28. The Genetics of Pre-eclampsia (GOPEC) consortium. Babies, pre-eclamptic mothers and grandparents: a 
three-generation phenotyping study. J Hypertens 2007; 25: 849-54. 
29. Hjartardottir S, Leifsson BG, Geirsson RT, Steinthorsdottir V. Paternity change and the recurrence risk in 
familial hypertensive disorder in pregnancy. Hypertens Pregnancy 2004; 23: 219-25. 
30. Serrano NC, Díaz LA, Páez MC, Mesa CM, Cifuentes R, Monterrosa A, et al. Angiotensin-converting en-
zyme I/D polymorphism and preeclampsia risk: evidence of small-study bias. PLoS Med 2006; 3 (12): e520. 
31. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classiﬁcation and diagnosis of 
the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hyperten-
sion in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20: IX-XIV. 
32. The Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven 
common diseases and 3,000 shared controls. Nature 2007; 447: 661-78. 
33. Manolio TA, Brooks LD, Collins FS. A HapMap harvest of insights in to the genetics of common disease. J 
Clin Invest 2008; 118: 1590-1605. 
34. Marchini J, Howie B. Genotype imputation for genome-wide association studies. Nature Rev Genet 2010; 11: 
499-511. 
35. The International HapMap 3 Consortium. Integrating common and rare genetic variation in diverse human 
populations. Nature 2010; 467: 52-8. 
36. The 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. 
Nature 2012; 491: 56-65. 
37. de Bakker P, Ferreira M, Jia X, Neale B, Raychaudhuri S, Voight B. Practical aspects of imputation-driven 
meta-analysis of genome-wide association studies. Hum Mol Genet 2008; 17: R122-8. 
38. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. Finding the missing 
heritability of complex diseases. Nature 2009; 461: 747-53. 
39. Kong A, Steinthorsdottir V, Masson G, Thorleifsson G, Sulem P, Besenbacher S, et al. Parental origin of 
sequence variants associated with complex diseases. Nature 2009; 462: 868-74. 
40. Milne F, Redman C, Walker J, Baker P, Bradley J, Cooper C, et al. The pre-eclampsia community guideline 
(PRECOG): how to screen for and detect onset of pre-eclampsia in the community. BMJ 2005; 330: 576-80. 
 
 
